cGxP.wire https://validator.w3.org/feed/docs/rss2.html Altimmune Reports Positive Phase 2 RECLAIM Results for Pemvidutide in Alcohol Use Disorder Dyne Secures FDA IND Clearance for DYNE-302 in FSHD Vector, Wynn Partner on Critical Care Drug Delivery Galmed Advances Brain-Targeted Aramchol for Parkinson’s RedHill Advances Opaganib for Emerging Ebola Outbreak Philips Reports Strong Q2 2026 Growth and AI Innovation Atea Pharmaceuticals Achieves Phase 3 Success in Hepatitis C Trial Antag Therapeutics Doses First Patient in Phase 2a Trial of AT7687 InnoCare Phase III TYK2 Study Meets Psoriasis Endpoint IceCure Launches ChoICE Study for ProSense in U.S. ViiV Healthcare Reports Positive Phase IIIb Dovato Results Cullinan Therapeutics Plans Registrational Phase 2 Trial for CLN-049 ICON Partners with Anthropic to Transform Clinical Trials with AI Akeso Doses First Patient in HER3 ADC Lung Cancer Trial Guardant Health Launches Patrick Dempsey Campaign for CRC Screening Masimo Earns FDA 510(k) for Pediatric Brain Monitoring Medicus Pharma Receives FDA Clearance for Registrational SkinJect Study Lexicon Pharmaceuticals Completes Enrollment in Phase 3 SONATA-HCM Trial DifGen Wins FDA IND Clearance for Breast Cancer Therapy Revagenix Doses First Patient in Phase 1 Rev-56 Trial Organogenesis Publishes Positive Affinity Trial Results for Venous Leg Ulcers Insilico Medicine Presents ISM6331 Phase 1 Data at ESMO CG Oncology Publishes Positive Phase 3 BOND-003 Results in The Lancet Oncology Xeltis Raises €20.5M to Advance aXess and US Expansion ProMIS Neurosciences Reports Positive Phase 1b PMN310 Interim Data bioAffinity Technologies Publishes Clinical Framework for CyPath Lung Humacyte FDA Accepts IND for First-in-Human CTEV CABG Study Calidi Biotherapeutics Highlights CLD-401 Cancer Therapy Data Kirin and Blackmores Launch Cognizin® Cognitive Supplements Seegene Targets New Global PCR Standard for Reproductive Health CSL Reports Positive Phase 3b Results for Pediatric ANDEMBRY HoneyNaps Expands AI Clinical Trial Analytics as CRO Waters Strengthens Clinical Diagnostics with Xevo XR Innovation Veru Completes Enrollment in Phase 2b PLATEAU Obesity Trial BioMarin Partners n-Lorem on First ReNU Syndrome Therapy Ascletis Reports ASC37 Shows Superior Weight Loss in Obesity Study IDEAYA Biosciences Advances IDE892 in MTAP-Deleted Cancers Bambusa Therapeutics Reports Positive Early Phase 1 Results for BBT001 in Atopic Dermatitis Biohaven and Yale Secure Major Win in MODA Technology Dispute Alexion, AstraZeneca Rare Disease Shares Phase 3 Ultomiris Trial Results Kelun-Biotech Advances First Dual-Payload ADC into Clinical Trials AstraZeneca’s Sone-Ve Delivers Phase III Survival Breakthrough MapLight Therapeutics Announces Positive Phase 2 Schizophrenia Data CAMP4 Therapeutics Receives Australian Clearance for First-in-Human CMP-002 Trial Neumora Therapeutics Announces Positive NMRA-215 Toxicology Findings Nova Biomedical Expands Cell Line Development Platform VERAXA Biotech and OmniAb Collaborate on VXA-222 Bispecific ADC Otsuka’s SIMTRIYO® Becomes First Approved NDSRI for ADHD Yarrow Bioscience Completes VYNE Merger, Advances YB-101 into Phase 2 Trial Glaukos Completes Enrollment in PRESERFLO MicroShunt Pivotal Study